Tin tức & Cập nhật

Mental wellbeing during a pandemic

24 Jan 2025 bởi

The recurrent waves of the COVID-19 pandemic are having a significant impact on healthcare workers, and Medical Protection has called for more to be done globally to ensure that medical professionals have quick access to mental wellbeing support.

Mental wellbeing during a pandemic

24 Jan 2025

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

11 Oct 2024 bởi

Pooled analysis of the ASSERT and ASSERT-EXT studies show sustained improvements in multiple parameters with odevixibat in individuals with Alagille syndrome (ALGS), thus reinforcing its role in the treatment of this multisystem genetic disorder.

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

11 Oct 2024

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

11 Sep 2024 bởi

The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

11 Sep 2024

Scenario 1

27 Aug 2024 bởi

Treatment with linaclotide significantly improved abdominal symptoms and the frequency of complete spontaneous bowel movements (CSBMs) among adult and elderly patients with irritable bowel syndrome with constipation (IBS-C), according to the pooled analysis of three phase III trials presented at DDW 2024.

Scenario 1

27 Aug 2024

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

22 Aug 2024 bởi

Systemic therapy plays a central role in the management of unresectable hepatocellular carcinoma (HCC). In this rapidly developing therapy area, recent clinical trials are redefining systemic treatments, including multiple kinase inhibitors (MKI). During the recent Gastro Lunch and Learn sessions sponsored by Eisai, Dr David Tai and Dr Yong Wei Peng discussed the evidence behind MKIs such as lenvatinib (Lenvima^®) in the treatment of unresectable HCC through a case-based approach.

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

22 Aug 2024

Digital Health and Telemedicine

16 Aug 2024

Exploring the rise of telehealth services, digital health records, and remote patient monitoring, and how these technologies are transforming healthcare delivery.

Digital Health and Telemedicine

16 Aug 2024

[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence

07 Aug 2024

People who inject drugs (PWID) with low adherence to sofosbuvir/velpatasvir can still be cured of hepatitis C virus (HCV) infection, suggests a study.

[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence

07 Aug 2024

Revealed: Hepatitis B viral load critical to infection clearance

05 Aug 2024 bởi

Out of about 400 million people with chronic hepatitis B virus (HBV), 75 percent of those infected live in the Asia Pacific region. Since HBV is strongly linked to the development of cirrhosis and liver cancer, the infection rate constitutes a significant public health challenge.

Revealed: Hepatitis B viral load critical to infection clearance

05 Aug 2024

$Oncolytic immunotherapy promising in sorafenib-refractory HCC$

Oncolytic immunotherapy promising in sorafenib-refractory HCC

02 Aug 2024 bởi

Asian patients with advanced hepatocellular carcinoma (HCC) refractory to sorafenib may benefit from an investigational oncolytic immunotherapy known as JX-594, as it showed antitumor activity in a recent phase II trial.

Oncolytic immunotherapy promising in sorafenib-refractory HCC

02 Aug 2024

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024 bởi

Maralixibat may have a role in treating a broader profile of children with PFIC, including those who have had biliary diversion surgery and those with MDR3 deficiency, suggest subgroup analyses from the phase III MARCH/MARCH-ON trials

Maralixibat may benefit certain subgroups of children with PFIC

28 May 2024

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Mental wellbeing during a pandemic

Mental wellbeing during a pandemic

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

[PD TEST]48-week data ASSERT odevixibat’s role in ALGS

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

Scenario 1

Scenario 1

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

Digital Health and Telemedicine

Digital Health and Telemedicine

[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence

[PD Test]HCV cure possible in people who inject drugs despite poor treatment adherence

Revealed: Hepatitis B viral load critical to infection clearance

Revealed: Hepatitis B viral load critical to infection clearance

Oncolytic immunotherapy promising in sorafenib-refractory HCC

Oncolytic immunotherapy promising in sorafenib-refractory HCC

Maralixibat may benefit certain subgroups of children with PFIC

Maralixibat may benefit certain subgroups of children with PFIC